FMS 250516 25.00P(FMS250516P25000) Stock Price Today

1.50
0.000.00%

15min DelayClose Mar 25 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Moomoo AI

Oct 31, 2023 21:33

Michael Sen and Helen Giza show confidence in Cordola's leadership for Care Delivery due to his extensive experience. They believe he'll be crucial for Fresenius Medical Care's ongoing transformation focusing on patient care.

Press Release: Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery

Analysts Notebook

Oct 16, 2023 17:00

Columns Novo Nordisk Sets New Record High: Analyzing the Market Effects of Popular GLP-1 Weight Loss Drugs

The increasing demand for GLP-1 weight-loss medications indicates that in the next ten years, a significant number of Americans may lose hundreds of millions of pounds collectively. This shift in weight could cause a redistribution of trillions of dollars.
Last week, $Novo-Nordisk A/S (NVO.US)$ presented evidence of a speeding trend when it announced that the primary component of Ozempic and Wegovy, ...

Meltyy

Oct 16, 2023 11:18

Stock Markets Rocked as Weight Loss Sweeps the Globe

Weight loss drugs lead the stock market
As GLP-1 diet drug companies have grown in influence, they have grown to be the new leaders of the stock market.
$Novo-Nordisk A/S (NVO.US)$ , with Wegovy and Ozempic in hand, is now Europe's largest company with a market capitalization of $433 billion, and the Danish drug giant's rapid growth has even had a direct impact on the Danish krone exchange rate and interest rates.
Meanwhile, $Eli Lilly and Co (LLY.US)$ , whic...

Weight-loss drugmakers report strong earnings: Boon or bane?

Moomoo News Global

Oct 13, 2023 05:28

Columns Ozempic, the Weight-Loss Drug, Steps Into Earnings Season Spotlight

Drugs used for weight loss like Ozempic pose a real risk to companies ranging from fast food restaurants to cigarette makers. Expect management teams of public companies to talk about them in their earnings calls.
Ozempic and Wegovy, two weight-loss medications, function by simulating the hormone that signals to people's brains when they are not hungry. Recent anecdotal data indicates that the medicine might reduce users' craving...

Weight-loss drugmakers report strong earnings: Boon or bane?

Moomoo Recap US

Oct 12, 2023 04:26

Columns Wall Street Today | Waller Says Fed 'Finally' Getting Good Inflation Data

MACRO
Waller Says Fed 'Finally' Getting Good Inflation Data
"In the last few months, we are finally getting very good inflation data that we wanted." Federal Reserve Governor Christopher Waller says at the annual E2 Summit in Park City, Utah. "If this continues, we're back to our target."
U.S. Stocks Trade Mixed After Fed Minutes, Wholesale Inflation Data
U.S. stocks were trading mixed Wednesday afternoon after the Federal ...

Israel-Hamas war: Oil prices & defense stocks surge on war fears

Market Insights

🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More